Literature DB >> 32060049

MicroRNA profiling of serum exosomes in patients with osteosarcoma by high-throughput sequencing.

Zhimeng Ye1, Zhuojun Zheng2, Linrui Peng3.   

Abstract

The microRNA expression profile of plasma exosomes in osteosarcoma needs to be further explored. The present study intends to investigate the practicality of plasma exosomal miRNAs as novel biomarkers of osteosarcoma. In the study, exosome-like vesicles were purified from the plasma of patients with osteosarcoma and healthy control. Differential centrifugation was used. The purified vesicles which ranged from 50 to 100 nm in size were identified as exosomes by transmission electron microscopy and western blot. Validating assays in vitro and in vivo were performed via CCK8, reverse transcription-quantitative PCR, flow cytometry, transwell and wound healing assays and xenograft model. High-throughput sequencing identified that 57 miRNAs, 20 of which were upregulated and 37 downregulated, were differentially expressed in patients with osteosarcoma and healthy control (p<0.01; fold change ≥3). In comparison to the controls, the expression levels of miR-92a-3p, miR-130a-3p, miR-195-3 p, miR-335-5 p, let-7i-3p were upregulated in the exosomes from patients with osteosarcoma with statistical significance. Studies in vitro and in vivo have proved that osteosarcoma-secreted exosomes from miR-195-3 p upregulated 143B osteosarcoma cells promote cell proliferation and invasion. Overall, the present study identified exosomal miRNAs with dysregulated expression in patients with osteosarcoma, and they may have potential as targets for the treatment of patients with osteosarcoma. © American Federation for Medical Research 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer; carcinoma; cell Proliferation

Mesh:

Substances:

Year:  2020        PMID: 32060049     DOI: 10.1136/jim-2019-001196

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  7 in total

Review 1.  Exosomes in osteosarcoma research and preclinical practice.

Authors:  Xiao-Bo Zhang; Rui-Hao Zhang; Xin Su; Jin Qi; Yi-Cun Hu; Jin-Tao Shi; Kai Zhang; Ke-Ping Wang; Hai-Yu Zhou
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  The mechanism by which noncoding RNAs regulate muscle wasting in cancer cachexia.

Authors:  Xueer Zhou; Shoushan Hu; Yunan Zhang; Guannan Du; Yi Li
Journal:  Precis Clin Med       Date:  2021-04-23

Review 3.  Exosomes in the tumor microenvironment of sarcoma: from biological functions to clinical applications.

Authors:  Huali Ye; Xin Hu; Yang Wen; Chongqi Tu; Francis Hornicek; Zhenfeng Duan; Li Min
Journal:  J Nanobiotechnology       Date:  2022-09-05       Impact factor: 9.429

4.  Extracellular Vesicles: A New Source of Biomarkers in Pediatric Solid Tumors? A Systematic Review.

Authors:  Nathalie S M Lak; Elvera J van der Kooi; Agustin Enciso-Martinez; Estefanía Lozano-Andrés; Cees Otto; Marca H M Wauben; Godelieve A M Tytgat
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

Review 5.  Role of extracellular vesicles in osteosarcoma.

Authors:  Qifan Yang; Jing Liu; Bo Wu; Xinyu Wang; Ye Jiang; Dong Zhu
Journal:  Int J Med Sci       Date:  2022-07-04       Impact factor: 3.642

Review 6.  Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma.

Authors:  Xiaozhuo Gao; Bo Gao; Shenglong Li
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

7.  Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma.

Authors:  Qiming Li; Xuedi Wang; Nian Jiang; Xianbiao Xie; Ni Liu; JunFeng Liu; Jingnan Shen; Tingsheng Peng
Journal:  Cancer Med       Date:  2020-07-16       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.